MDMX/MDM2-IN-2 is a potent dual inhibitor of p53-MDM2/MDMX, demonstrating dissociation constants (Kis) of 0.23 μM for MDM2 and 2.45 μM for MDMX. It effectively disrupts the interaction between p53 and MDM2 proteins, thereby reinstating p53 functionality to induce cell cycle arrest and apoptosis. Additionally, this compound impedes cell migration and invasion, exhibiting notable antitumor activity [1].

RO-5963 is a dual inhibitor of p53-MDM2 and p53-MDMX (IC50s: ~17 nM and ~24 nM, respectively).

Sulanemadlin (ALRN-6924) is a potent peptidomimetic macrocycle that serves as an inhibitor of the p53-MDM2 and p53-MDMX protein-protein interactions. It is capable of inhibiting either or both of these interactions, positioning it as a valuable tool for cancer research [1].

SJ-172550 is a small molecule inhibitor of MDMX (EC50: 5 μM).

MMRi64 is a specific inhibitor of Mdm2-MdmX E3 ligase activity.MMRi64 potently induces p53 accumulation and apoptosis in the p53 pathway in leukemia/lymphoma cells, disrupts Mdm2-MdmX interactions, and downregulates Mdm2 and MdmX in leukemia cells.MMRi64 MMRi64 can be used in cancer research.

RO2443 is a dual inhibitor of the MDM2-p53 or MDMX-p53 protein-protein interaction, inducung MDM2 and MDMX dimerization and activating the p53 pathway.

ATSP-7041 is a novel potent and selective dual inhibitor of mdm2 (ki = 0.9 nm) and mdmx (ki = 7 nm)

XI-006 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.

NSC 146109 hydrochloride is an activator of p53 targeting MDMX. NSC 146109 hydrochloride can be used for studies on breast cancer.

WK-298 is an effective MDM2/MDMX-p53 interaction inhibitor.